Log in to search using one of your social media accounts:

 

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Hormone Therapy Prolongs PFS in Low-grade Serous Cancer Hormone Therapy Prolongs PFS in Low-grade Serous Cancer
Hormone maintenance therapy prolongs progression-free survival, if not overall survival, in low-grade serous carcinoma following surgery and chemotherapy compared with routine observation alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Hormonal maintenance therapy may improve survival in women with rare serous carcinoma
For women with a rare subtype of chemo-resistant epithelial ovarian or peritoneum cancer, hormone maintenance therapy may significantly improve survival, according to a new study in theJournal of Clinical Oncology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 22, 2017 Category: Science Source Type: news

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peri
(University of Texas M. D. Anderson Cancer Center) For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2017 Category: Cancer & Oncology Source Type: news

Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous Carcinoma
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well. (Source: CancerNetwork)
Source: CancerNetwork - January 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

Low-Grade Serous Carcinoma of the Ovary
Low-grade serous ovarian cancer is a rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. In the upfront setting, treatment recommendations mimic those of high-grade serous ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 15, 2016 Category: Cancer & Oncology Authors: Rachel N. Grisham, MD Tags: Gynecologic Cancers Oncology Journal Ovarian Cancer Source Type: news

Ovarian Cancer: HMT Extends Survival (CME/CE)
(MedPage Today) -- Benefit seen in low-grade serous carcinoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 1, 2016 Category: Hematology Source Type: news

Tandem duplicate phenotype detected in triple-negative breast, other cancers
(Jackson Laboratory) A genomic configuration described as a tandem duplicator phenotype is significantly enriched in triple-negative breast cancer, serous ovarian cancer and endometrial carcinomas, and responds to cisplatin chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 4, 2016 Category: Cancer & Oncology Source Type: news

MD Anderson's David M. Gershenson, MD, Receives IGCS's Award for Excellence in Gynecologic Oncology
For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence. Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.The IGCS is a not-for-prof...
Source: M. D. Anderson Cancer Center - News Releases - November 10, 2014 Category: Cancer & Oncology Source Type: news

Large Study Points to Similarities Between Endometrial and Ovarian Cancers
OCRF SAC member Doug Levine, MD has found similarities between endometrial and ovarian cancers.According to a large new study published May 2, 2013 in the prestigious journal Nature, researchers have found that endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup, and may respond to targeted drugs already being tested in clinical trials.  Furthermore, they found that genomic alterations in uterine serous tumors—the most dangerous of the uterine lining-- share many features with high-grade serous ovarian cancer and basil-like breast cancers.This important study was un...
Source: OCRF News - May 2, 2013 Category: Cancer & Oncology Source Type: news

Researchers discover breakthrough in ovarian cancer
(St. Joseph's Hospital and Medical Center) Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 14, 2013 Category: Global & Universal Source Type: news

Genes Related To Aggressive Endometrial Cancer Identified
In a major breakthrough for uterine serous carcinoma (USC) - a chemo-resistant, aggressive form of endometrial cancer, Yale researchers have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. The collaborative team - which included researchers with expertise in gynecological cancer, genomics, and computational biology - identified a number of new genes that are frequently mutated in USC. The results of this comprehensive genetic analysis of USC are published in Proceedings of the National Academy of Sciences (PNAS) online early edition... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 30, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Genes behind aggressive endometrial cancer
In a major breakthrough for uterine serous carcinoma (USC) -- a chemo-resistant, aggressive form of endometrial cancer, researchers have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 28, 2013 Category: Science Source Type: news

Researchers find genes behind aggressive endometrial cancer
(Yale University) In a major breakthrough for uterine serous carcinoma (USC) -- a chemo-resistant, aggressive form of endometrial cancer, Yale researchers have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 28, 2013 Category: Global & Universal Source Type: news